Welcome to our dedicated page for Arcus Bioscience SEC filings (Ticker: RCUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Arcus Biosciences, Inc. (NYSE: RCUS) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures, including current reports on Form 8‑K and other key documents filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company focused on oncology and inflammatory and autoimmune diseases, Arcus uses SEC filings to report material clinical, financial and corporate events that can be important for investors analyzing RCUS stock.
Form 8‑K current reports frequently highlight significant developments in Arcus’s pipeline and capital structure. For example, 8‑K filings describe the discontinuation of the Phase 3 STAR‑221 trial and the Phase 2 EDGE‑Gastric study after an interim overall survival analysis showed no benefit for the domvanalimab plus zimberelimab and chemotherapy regimen compared with nivolumab plus chemotherapy. Other 8‑Ks detail updated data from the ARC‑20 Phase 1/1b study of casdatifan in metastatic clear cell renal cell carcinoma, including progression-free survival and response metrics, as well as safety findings.
Filings also cover financing and capital markets transactions. One Form 8‑K outlines an underwriting agreement for a public offering of common stock, including the number of shares sold, pricing and net proceeds. Another 8‑K describes a First Amendment to the company’s Loan and Security Agreement with Hercules Capital and other lenders, which restructures remaining term loan commitments into milestone-based tranches tied to Phase 3 data and potential FDA approval, extends the maturity date and adds performance covenants linked to market capitalization, qualified cash levels and potential net product revenue thresholds.
Investors can also use SEC filings to track collaboration and licensing arrangements, such as disclosures related to Arcus’s long-term collaboration with Gilead Sciences and its option and license agreement with Taiho Pharmaceutical. These documents may reference option exercises, milestone structures and rights to co-develop or commercialize investigational medicines like casdatifan, domvanalimab, zimberelimab and quemliclustat in specific territories.
Stock Titan’s interface surfaces these filings alongside AI-powered summaries that explain the practical implications of each document. Instead of parsing detailed legal language alone, readers can review concise explanations of how a loan amendment changes Arcus’s access to capital, what a trial discontinuation means for a particular program, or how a new data disclosure from a Phase 1/1b or Phase 3 study might influence the company’s development strategy. Real-time updates from EDGAR, combined with these AI insights, help users follow Arcus’s quarterly results, material clinical events, financing decisions and collaboration milestones directly from the underlying SEC record.
Arcus Biosciences reported that it is discontinuing its Phase 3 STAR-221 study after an interim analysis showed that the domvanalimab-based regimen did not improve overall survival compared with nivolumab plus chemotherapy in first-line advanced gastric and esophageal cancers. A related Phase 2 EDGE-Gastric study will also be stopped. An Independent Data Monitoring Committee recommended ending the trial for futility, although the safety profile of the domvanalimab combination was similar to the control arm with no new safety issues identified.
The company and its partner Gilead are working with investigators on next steps for patients and will further analyze the data. Arcus stated that, based on its existing cash, cash equivalents and marketable securities, it expects to fund planned operations until at least the second half of 2028. R&D efforts will shift toward casdatifan, a potential best-in-class HIF-2a inhibitor, and early inflammation and autoimmune programs, including an MRGPRX2 inhibitor expected to enter clinical testing in 2026.
Arcus Biosciences, Inc. reported an insider stock sale by its president. A Form 4 filing shows that on 12/04/2025, the executive sold 82,997 shares of Arcus common stock at a weighted average price of $24.7069 per share, in multiple trades within a price range of $24.35 to $25.15. After these transactions, the reporting person beneficially owned 954,063 shares indirectly through a trust and 367,220 shares directly. The filing notes that the sales were made under a Rule 10b5-1 trading plan adopted on August 8, 2025, which is designed to allow pre-arranged trading independent of day-to-day market conditions.
Arcus Biosciences insider plans additional stock sale under Rule 144. The Juan Carlos Jaen and Anita Galeana 2000 Trust filed a notice to sell 82,997 shares of Class A common stock of Arcus Biosciences through Goldman Sachs & Co. LLC on the NYSE, with an aggregate market value of approximately $2,096,504.22. The filing notes that 120,801,086 shares of this class were outstanding at the time of the notice.
The trust originally acquired these shares from the issuer in a private transaction on 05/08/2015. Over the prior three months, the trust reported multiple open-market sales of Arcus Class A common stock, including 19,019 shares on 10/28/2025 and 77,167 shares on 10/29/2025, along with several smaller transactions, for total disclosed gross proceeds in the millions of dollars. The signatory represents that they are not aware of any undisclosed material adverse information about Arcus Biosciences.
Arcus Biosciences Chief Accounting Officer reports option exercise and share sale. On 11/26/2025, the officer exercised a stock option to acquire 1,900 shares of Arcus Biosciences common stock at $13.33 per share and on the same date sold 1,900 shares at $26 per share under a Rule 10b5-1 trading plan. After these transactions, the officer directly beneficially owned 27,363 shares of common stock and 9,500 stock options with a $13.33 exercise price, which are scheduled to become exercisable in 48 equal monthly installments after January 1, 2025 and expire on January 22, 2035.
Arcus Biosciences (RCUS) Chief Financial Officer reports stock sale under pre-arranged plan. The CFO sold 5,000 shares of Arcus Biosciences common stock on 11/26/2025 at a price of $25 per share in an open market sale coded as an "S" transaction. After this sale, the reporting person beneficially owns 87,138 shares of Arcus Biosciences common stock in direct ownership. The filing states that the sale was made under a Rule 10b5-1 trading plan, which is a pre-established program intended to allow insiders to sell shares according to set instructions.
Arcus Biosciences, Inc. (RCUS)November 17, 2025, a trust associated with the reporting person sold 37,114 shares of common stock at a weighted average price of $20.2274, and a further 7,836 shares at a weighted average price of $20.713. On November 18, 2025, the trust sold an additional 5,050 shares at a weighted average price of $19.75. The filing states these transactions were executed under a Rule 10b5-1 trading plan adopted on August 8, 2025. After these sales, the reporting person beneficially owned 1,037,060 shares indirectly through a trust and 367,220 shares directly.
Arcus Biosciences (RCUS) insider holders filed a notice to sell 50,000 shares of Class A common stock through Goldman Sachs & Co. LLC on the NYSE, with an indicated aggregate market value of $999,500. The filing states that 120,801,086 shares of this class were outstanding at the time referenced, providing context for the planned sale size. The shares were originally acquired from the issuer in private transactions in May 2015. Over the past three months, the same trust has already sold additional Class A shares in several transactions, including 77,167 shares on 10/29/2025 for gross proceeds of $1,617,034.48. The signer represents that they are not aware of undisclosed material adverse information about the company.
Arcus Biosciences (RCUS): Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen filed an amended Schedule 13G reporting beneficial ownership of 4,332,479 Arcus common shares, equal to 4.1% of the class as of September 30, 2025.
The reporting persons have 0 shares with sole voting or dispositive power and 4,332,479 shares with shared voting and shared dispositive power. They certified the holdings were not acquired with the purpose or effect of changing or influencing control.
Arcus Biosciences (RCUS) reported an insider transaction by its Chief Operating Officer. On 11/07/2025, the officer exercised 50,291 stock options at $1.2276 per share and sold 50,291 common shares at a $18.9709 weighted average price under a Rule 10b5-1 trading plan. After these trades, the officer directly held 214,232 common shares. The filing notes the sales occurred across multiple trades between $18.59 and $19.42. Remaining derivative holdings include 80,583 stock options with an expiration date of 03/14/2027.
Gilead Sciences filed Amendment No. 6 to its Schedule 13D on Arcus Biosciences, updating its beneficial ownership and voting power disclosures. Gilead reports beneficial ownership of 31,424,760 shares of Arcus common stock, representing 25.6% of the class. Gilead has sole voting and dispositive power over the same 31,424,760 shares and no shared power.
The percentage is based on 122,856,086 shares outstanding as reported in a prospectus supplement dated October 31, 2025. The filing details prior purchases under multiple purchase agreements and offerings. It also notes that Jeffrey A. Bluestone holds options exercisable within 60 days for 10,750 shares, equating to 0.01% on an as‑converted basis.
FAQ
What is the current stock price of Arcus Bioscience (RCUS)?
What is the market cap of Arcus Bioscience (RCUS)?
